

FINAL AGENDA
Center Outcomes Forum
WebEx

Friday, November 20, 2020; 11:00 AM – 3:30 PM CDT

Time	Min	Topic	Speaker
11:00 – 11:10	10	Welcome and Introductions	J. Douglas Rizzo, MD, MS
11:10 – 12:10	60	<p>Is minimal residual disease (MRD) for acute leukemia (AML, ALL) ready for use as a risk adjustment factor in the CSA?</p> <ul style="list-style-type: none"> ▫ If not, what criteria need to be met in the future (e.g., consistent/standardized measures, etc.)? ▫ What changes in data collection should CIBMTR make to support future use of MRD? 	<p>Daniel Weisdorf, MD*</p> <p>Stella M. Davies, MBBS, PhD, MRCP^</p> <p>Chris Hourigan, DM, DPhil^</p> <p>Selina Luger, MD^</p> <p>Wael Saber, MD, MS^</p> <p>Bart Scott, MD^</p>
12:10 – 12:20	10	Break	
12:20 – 1:20	60	Are there new approaches to account for social determinants of health in the CSA risk adjustment model?	<p>Navneet Majhail, MD, MS*</p> <p>Kira Bona, MD, MPH^</p> <p>Luciano Costa, MD, PhD^</p> <p>Terri Hahn, PhD^</p> <p>Richard Maziarz, MD^</p> <p>Tatenda Mupfudze, PhD^</p> <p>Ron Potts, MD^</p>
1:20 – 1:40	20	Break	

Time	Min	Topic	Speaker
1:40 – 2:40	60	Can CIBMTR adequately adjust for the impact of the COVID-19 pandemic in the CSA? <ul style="list-style-type: none"> ▫ What factors are most essential and how can they be incorporated in the risk adjustment? 	John Wingard, MD* Kwang Woo Ang, PhD^ Christopher Dandoy, MD^ Miguel Perales, MD^ Bill Wood, MD, MPH^
2:40 – 2:50	10	Break	
2:50 – 3:10	20	CSA research project proposals (brief summary and plans) <ul style="list-style-type: none"> ▫ Impact of CSA on HCT volumes ▫ Impact of CSA on HCT outcomes ▫ Impact of CSA on access/patient selection 	Wael Saber, MD, MS Akshay Sharma, MD Leslie Lehmann, MD Mark Juckett, MD, MHCM
3:10 – 3:30	20	Update on consequences of CSA public reporting	Navneet Majhail, MD, MS J. Douglas Rizzo, MD, MS

***Moderator ^Panelist**